Gilead’s Kite subsidiary has reported new data from the main trial for its CAR-T Yescarta, hoping to encourage greater use of the slow-growing therapy. Updated results from the ZUM
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.